Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Celle

724 clinical trials in Celle, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Celle at a glance
724
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

724 trials in Celle

Open in trial search

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Pasteur Inc.

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Obesity+1

Recruiting

Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Diabetes mellitus+2

Recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Celle

What the registry says about research in the country

01 Breast Cancer Research

Clinical studies focusing on triple-negative breast cancer and HER2-negative breast cancer, evaluating innovative treatment approaches in both early and advanced stages of the disease.

  • Advanced Treatment Protocols
  • Chemotherapy Combinations
  • Hormone Receptor Studies

Investigations combining immunotherapy with traditional chemotherapy regimens, aiming to improve survival rates and treatment outcomes for breast cancer patients.

02 Immunotherapy Research

Groundbreaking studies exploring the effectiveness of atezolizumab in combination with established chemotherapy protocols for breast cancer treatment.

  • Neoadjuvant Therapy
  • Adjuvant Treatment
  • Event-Free Survival Analysis

Research focusing on measuring survival rates and analyzing treatment response patterns in advanced breast cancer patients.

03 Molecular Patterns Analysis

Comprehensive research investigating spatial and temporal patterns in breast cancer treatment responses, with particular focus on drug efficacy and resistance mechanisms.

  • Treatment Resistance Studies
  • Progression-Free Survival
  • Overall Survival Analysis

Studies examining therapeutic outcomes in hormone receptor-positive breast cancer patients undergoing first-line treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.